Make Your Lab Greener with ZooMAb Recombinant Antibodies

Make Your Lab Greener with ZooMAb Recombinant Antibodies

When thinking of ways to make your lab more sustainable, antibodies may not be at the forefront of your mind. However, many common antibody reagents have a substantial environmental footprint, meaning that even a simple switch can have a big impact. ZooMAb® recombinant antibodies are a greener alternative to traditional antibodies that are easily introduced into existing workflows, where they can also enhance experimental reproducibility. Recently, ZooMAb® recombinant antibodies became the first ever antibodies to be recognized for their low environmental impact by My Green Lab, a non-profit organization dedicated to creating a culture of sustainability in science.

What are ZooMAb® recombinant antibodies?

ZooMAb® recombinant antibodies are produced using a proprietary B cell immortalization technology that improves survival rates over traditional techniques to capture the highest diversity of antibodies against the target of interest. Following immortalization, the B cells are rapidly screened to identify the highest-affinity, most specific antibody candidates from this broad diversity. Each prospective antibody candidate is then cloned into a recombinant vector for in vitro expression, allowing for application-specific testing to ensure that it is both versatile and suitable for multiple applications relevant to the research on the target of interest. Once top-performing clones have been selected, they are purified to homogeneity in a simple phosphate buffered saline (PBS) with trehalose, a sugar composed of two molecules of glucose, without any preservatives, biocides, or carrier proteins. They are then precisely dispensed in 25 µL amounts for lyophilization, giving the antibody its greatly enhanced stability.

Benefits for the environment

While traditional antibodies are shipped with a cardboard outer box, polystyrene cooler box, and large quantities of either wet or dry ice, ZooMAb® recombinant antibodies are shipped at ambient temperature in SMASH packaging, a greener alternative to conventional packaging that is being applied across MilliporeSigma’s life science portfolio. Ambient shipping provides the benefits of reduced waste and decreased energy use, both for manufacturing and transporting bulky packaging, translating to lower shipping charges for users, and is made possible by the fact that ZooMAb® recombinant antibodies are lyophilized. The improved antibody stability afforded by lyophilization also helps to keep potentially hazardous chemicals (e.g., sodium azide) and carrier proteins of animal origin (e.g., BSA) out of experiments and the environment as they are not required for stabilization purposes. Another important advantage of ZooMAb® recombinant antibodies is that animal use is greatly reduced compared to producing traditional polyclonal antibodies.

Environmental benefits of ZooMAb® recombinant antibodies

  • ZooMAb® recombinant antibodies are shipped at ambient temperature, reducing waste and energy use while minimizing shipping charges for users
  • The improved stability afforded by lyophilization allows for ZooMAb® antibodies to be simply formulated in PBS with trehalose, helping to keep potentially hazardous chemicals (e.g., sodium azide) and proteins of animal origin (e.g., BSA) out of experiments and the environment
  • ZooMAb® recombinant antibodies are produced with significantly reduced animal use compared to traditional polyclonal antibodies

Benefits for scientific research

Besides providing environmental benefits, ZooMAb® recombinant antibodies offer many advantages for scientific research. Critically, the proprietary method used for producing ZooMAb® antibodies gives them superior specificity, affinity, and reproducibility compared with traditional antibodies. In addition, the rabbit origin of the inaugural set of ZooMAb® recombinant antibodies allows for the targeting of immunogens that are known to present challenges in mice, including small molecules (compounds of <600 kDa), peptides, and post-translational modifications (PTMs). It should also be noted that the simple formulation of ZooMAb® recombinant antibodies makes them suitable for use in both in vivo and in vitro applications, and is compatible with most commercial antibody labeling kits, giving researchers greater flexibility for experimental design.

Award-winning innovation

In 2020, the ZooMAb® recombinant monoclonal antibody platform received CiteAb’s ‘Innovative Product of the Year’ award in recognition of its potential to change the research reagent sector worldwide. This accolade has more recently been complemented by an Accountability, Consistency and Transparency (ACT) label from My Green Lab, when the ZooMAb® recombinant antibody platform received the lowest Environmental Impact Factor (EIF) scores in My Green Lab’s chemicals and reagents category. Importantly, the ACT label enables scientists to choose more sustainable products for their research.

To learn more about how ZooMAb® recombinant antibodies can decrease your environmental impact while increasing your experimental reproducibility, visit SigmaAldrich.com/greenz

MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany.

BlueskyReddit
Emma Mason is the founder and director of Cambridge Technical Content Ltd, based in the U.K. Since graduating with a bachelor’s degree in biology from the University of Kent at Canterbury in 2000, she has gained extensive experience developing and running immunoassays within companies including Millennium Pharmaceuticals, AstraZeneca and Cellzome. She now produces a wide range of scientific content, including regular features for Biocompare.
September 20, 2023

About the Author:

Emma Mason is the founder and director of Cambridge Technical Content Ltd, based in the U.K. Since graduating with a bachelor’s degree in biology from the University of Kent at Canterbury in 2000, she has gained extensive experience developing and running immunoassays within companies including Millennium Pharmaceuticals, AstraZeneca and Cellzome. She now produces a wide range of scientific content, including regular features for Biocompare.

Join the Discussion